/
Oncology
Synovial Sarcoma
5
Pipeline Programs↗
4
Active Trials↗
7
Companies Involved↗
Synovial Sarcoma is an early-stage landscape with 5 programs across 7 companies. The most active players are Roche. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 11
Phase 2
No programs
Approved
No programs
Analysis
Modality Breakdown
80%
Small molecule
4 of 5 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 100% of 5 pipeline programs.
Analysis
Trial Status
21
clinical trials
Terminated8 · 38%
Completed5 · 24%
Recruiting3 · 14%
Withdrawn3 · 14%
Active, not recruiting1 · 5%
Available1 · 5%
Clinical Trials
Trial Activity
21 trials
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
Recruiting·—·Phase 3·NCT07174427·5 enrolled
Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00052754·48 enrolled
Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma
Completed·—·Phase 1/2·NCT03250325·8 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)